We are a biopharmaceutical company focused on the discovery and development of novel therapeutics to treat metabolic diseases including nonalcoholic steatohepatitis (NASH).Suggesting new paradigms of metabolic disease treatment, Glaceum is developing integrated therapies to meet the needs of those living with obesity, liver disease, and type 2 diabetes.We are committed to a universal treatment for patients with metabolic disease by restoring their homeostatic balance.Our corporate headquarters is located in Su-Won, South Korea. For more information about Glaceum, please visit our website at: www.glaceum.com and contact us at: bd@glaceum.com or ir@glaceum.com.